Cytogenetic and molecular features of lenalidomide-associated ALL. Oncoprint depicting somatic alterations and rearrangements/fusions identified by one of several NGS panels and targeted RNA-seq panels (eg, FoundationOne Heme and Archer FusionPlex) identified in evaluable patients developing B-ALL after lenalidomide therapy, including single-nucleotide variations (SNVs), insertions, copy number loss, deletions, and splicing variants. Dark grey boxes indicate the target gene/fusion was not evaluated in that patient; ∗, FoundationOne Heme panel includes RNA-seq.